Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped up prior to trading on Monday. The stock had previously closed at $21.20, but opened at $21.92. Chugai Pharmaceutical shares last traded at $21.5112, with a volume of 1,627 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on CHGCY. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Nomura upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Chugai Pharmaceutical currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 1.3%

The firm has a market capitalization of $71.82 billion, a PE ratio of 23.72 and a beta of 0.60. The business’s fifty day moving average price is $20.76 and its 200 day moving average price is $22.85.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. On average, analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.